Results 101 to 110 of about 52,965 (242)

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

IRRITABLE BOWEL SYNDROME IN CHILDREN: DIAGNOSTICS AND MODERN APPROACHES TO THERAPY

Педиатрическая фармакология, 2006
In the article modern data on prevalence, diagnostic criteria and approaches to the treatment of irritable bowel in children are presented. The issues of the terminology and classification of recurrent abdominal pains in children are clarified, the basic
S.Yu. Tereshchenko
doaj   +2 more sources

Diagnostic potential of various laboratory tests for irritable bowel syndrome (IBS): a systematic review

Journal of the Pakistan Medical Association
Objective: To identify possible tests along with their accuracies that may be used to diagnose irritable bowel syndrome. Method: The systematic review comprised literature search on Cochrane Library, PubMed, Science Direct and Elsevier databases for ...
Misha Mansoor, Muhammad Hamza Shafiq, Mahnoor Imran, Fiza Mushtaq, Sana Iftikhar, Fuad Shafiq   +5 more
doaj   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Tenapanor Beyond Phosphate: Gut Sodium Transport, Stool Transit Time, and Volume Balance in Dialysis Patients

Hemodialysis International, EarlyView.
ABSTRACT Introduction Tenapanor, a minimally absorbed intestinal NHE3 inhibitor approved for hyperphosphatemia in dialysis, lowers phosphate and reduces intestinal sodium absorption. Its sodium–water signal may have implications beyond phosphate but remains poorly separated from diarrhea‐mediated losses and dialysis prescription artifacts. Methods This
Lucas Maciel de Almeida Corrêa, Luiggi Kevin Virgino Brandão, Clara Belo Gamon Santiago, Alexandre de Assis Barbosa, Gabriel Rian Mazur, Gabriel Costa de Santana, Yan Roberth Delmiro Silva, Letícia Esteves Dante, Ivan Felipe Dutra Júnior   +8 more
wiley   +1 more source

Can Artificial Intelligence Be Utilised to Develop Point‐of‐Care Endodontic Microbiological Technologies?

International Endodontic Journal, EarlyView.
ABSTRACT Background Primary or persistent endodontic disease is caused by microbial biofilms that irritate the pulp and periapical tissues. Extensive microbiological analyses of these biofilms and their constituent pathogens have revealed their diversity and complexity.
Ashraf F. Fouad
wiley   +1 more source

The Gut Microbiome as a Therapeutic Target in Alopecia Areata: Not Yet Part of the Patient Treatment Plan

International Journal of Dermatology, EarlyView.
ABSTRACT Interest in the gut microbiome as a therapeutic target for treating alopecia areata (AA) has grown considerably. However, existing evidence remains limited and inconsistent. Currently, there is insufficient evidence to recommend microbiome‐directed testing and therapies to patients with AA.
Eric McMullen, Deema Abdel Hafeez, Nikhil Pai, Laurence Mainville, Shireen Dumont, Narachai Julanon, Romy Shenderey, Grace Xiong, Shahnawaz Towheed, Jeffrey Donovan   +9 more
wiley   +1 more source